Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 237 of 6351
-
Light pulses to the eye: a new hope against dry AMD?
Disease control Recruiting nowThe purpose of this registry study is to collect real life data pertaining to the safety and clinical effectiveness of multi-wavelength photobiomodulation (PBM) as provided by the Valeda Light Delivery System in participants with dry age-related macular degeneration (AMD) in rout…
Sponsor: LumiThera, Inc. • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Can a new drug erase the last traces of leukemia?
Disease control CompletedThere is currently no available treatment, capable to increase the rate of sustained deep molecular remissions after TKI discontinuation in CML. Venetoclax could be such a drug. The study will provide unprecedented biological insights on the effects of venetoclax in controlling m…
Phase 2 • Sponsor: Thomas Ernst, PD Dr. med. • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
Gene-Guided chemo cocktail aims to tame tough pancreatic cancer
Disease control Recruiting nowThis is a single-centre, non-randomized, open label phase II trial to be conducted at the National Cancer Centre, Singapore (NCCS). Patients diagnosed with metastatic PDAC will be eligible to enrol. The investigators hypothesize the anticancer activity of low dose OXIRI (LD-OXIR…
Phase 2 • Sponsor: National Cancer Centre, Singapore • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Could this pill ease Alzheimer's hallucinations?
Symptom relief Recruiting nowThis is a Phase 3, randomized, double-blind, placebo-controlled, parallel group study to evaluate the safety and efficacy of KarXT in male and female subjects who are aged 55 to 90 years and have mild to severe Alzheimer's Disease (AD) with moderate to severe psychosis related to…
Phase 3 • Sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company • Aim: Symptom relief
Last updated Sep 06, 2026 00:00 UTC
-
New psoriasis drug shows promise in large trial
Disease control CompletedThis is a multicenter, randomized, double-blind, parallel, placebo-controlled Phase III clinical study to evaluate the efficacy and safety of JS005 in 702 adult patients with moderate-to-severe chronic plaque psoriasis
Phase 3 • Sponsor: Shanghai Junshi Bioscience Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New asthma drug could help kids breathe easier
Disease control Recruiting nowTo assess the efficacy and safety of tezepelumab in pediatric participants with severe uncontrolled asthma on medium to high-dose inhaled corticosteroids (ICS) and at least one additional asthma controller medication with or without oral corticosteroids.
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Epigenetic drug may re-sensitize liver tumors to immunotherapy
Disease control OngoingFor hepatocellular carcinoma (HCC), durable responses and improved survivals have been reported in clinical trials on immune checkpoint inhibitor (ICI)-based treatment. However, resistance to ICI is increasingly encountered in clinical practice in HCC patients. Various approache…
Phase 2 • Sponsor: Stephen Chan Lam • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New triple therapy aims to control cystic fibrosis Long-Term
Disease control By invitation onlyThe purpose of this study is to evaluate the long-term safety, tolerability, and efficacy of vanzacaftor/tezacaftor/deutivacaftor (VNZ/TEZ/D-IVA) in participants with cystic fibrosis (CF).
Phase 3 • Sponsor: Vertex Pharmaceuticals Incorporated • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Gene therapy shot aims to cut eye injections for diabetic vision loss
Disease control OngoingPhase 2 randomized, active-controlled, double-masked, dose-ranging trial in adults with Diabetic Macular Edema (DME).
Phase 2 • Sponsor: 4D Molecular Therapeutics • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
New drug aims to slow kidney failure in IgA nephropathy patients
Disease control OngoingThe purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of sefaxersen (RO7434656), a novel Antisense Oligonucleotide (ASO) therapy in participants with primary IgA nephropathy (IgAN) who are at high risk of progressive kidney disease despite optimized …
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Can a new daily pill slow advanced prostate cancer?
Disease control Recruiting nowThe purpose of this study is to assess the safety, tolerability and preliminary efficacy of HRS-5041 in men with progressive metastatic castration resistant prostate cancer. The objective of this study was to determine the dose-limiting toxicity, maximum tolerance and recommended…
Phase 1 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Can a brain zapping technique and online therapy fix sleep in depressed teens?
Disease control CompletedThis study evaluated whether combining an internet-delivered Acceptance and Commitment Therapy program with intermittent theta burst stimulation improves subjective sleep quality in adolescents with depressive disorders and sleep disturbances. Acceptance and Commitment Therapy is…
Sponsor: Central China Normal University • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New drug cocktail aims to beat back tough leukemia
Disease control Recruiting nowThe purpose of this study is to compare the efficacy and safety of venetoclax combined with CACAG regimen with BAT regimen in the treatment of relapsed/refractory acute myeloid leukemia.
Phase 2 • Sponsor: Chinese PLA General Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Could removing the gallbladder stop mystery pancreatitis attacks?
Prevention Recruiting nowRationale: Annually, acute pancreatitis is diagnosed in 6,500 patients in the Netherlands. In up to 25% of patients no definitive cause can be determined after routine work-up including endoscopic ultrasound and this is deemed to be idiopathic acute pancreatitis (IAP). IAP is kno…
Sponsor: M.G. Besselink • Aim: Prevention
Last updated Aug 05, 2026 00:00 UTC
-
Can a pill save your sight? new trial targets blinding eye disease
Disease control OngoingThis Phase 3, multicenter, double-masked, parallel-group, placebo-controlled, randomized, fixed-dose clinical study is designed to evaluate the efficacy and safety of tinlarebant (LBS-008) in subjects diagnosed with GA.
Phase 3 • Sponsor: Belite Bio, Inc • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
Can a smart drug home in on Hard-to-Treat cancers?
Disease control OngoingThis is a global, multi-center, open-label, Phase I/II first-in-human study of XNW27011 monotherapy as an investigational product (IP) in patients with locally advanced and/or metastatic solid tumors who have failed or are intolerant to standard therapies. XNW27011 is an antibody…
Phase 1/2 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New drug could protect Babies' brains after birth complications
Disease control Recruiting nowHypoxic-ischemic encephalopathy (HIE) affects approximately 4,000 to 12,000 persons annually in the United States. Mortality from HIE has been reported up to 60%, with at least 25% of survivors left with significant neurocognitive disability. Despite this vital unmet medical need…
Phase 2 • Sponsor: ReAlta Life Sciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Engineered immune cells take aim at tough lung cancer
Disease control OngoingThis is a phase 1, first-in-human, open-label, multicenter, dose escalation and expansion study of DLL3-targeted chimeric antigen receptor T-cells in subjects with extensive stage small cell lung cancer or large cell neuroendocrine lung cancer.
Phase 1 • Sponsor: Legend Biotech USA Inc • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Hope for kids with leukemia: new drug combo aims to boost remission
Disease control PausedThis is a phase 2 study to test the hypothesis that venetoclax in combination with standard chemotherapy will be tolerable and active in pediatric patients with newly diagnosed acute myeloid leukemia (AML). Primary Objectives: * Establish the tolerability adding venetoclax to s…
Phase 2 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
Could a diabetes drug reverse liver scarring?
Disease control OngoingConduct a community intervention study that will 1) validate a screening approach to identify patients at risk for advanced NAFLD in the obese or T2DM population, and 2) test whether semaglutide treatment is effective for the management of significant fibrosis due to NAFLD in hig…
Phase 2 • Sponsor: University of California, San Diego • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC